When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
IOVA - Genocea's Positive Cancer Data Leads To A Potential Catalyst Opportunity In 2020
Iovance Biotherapeutics Inc.
Genocea Biosciences (GNCA) presented some outstanding immunogenicity data at the American Society for Clinical Oncology ((ASCO)) 2019 medical meeting. It highlighted initial data from its phase 1/2a study using its neoantigen vaccine GEN-009. While this was just immunogenicity data, it was quite promising. Especially because it sets up for another potential catalyst in 2020. In order to diversify its neoantigen platform, the biotech is even advancing a neoantigen T-cell therapy known as GEN-011. This should act as a backup product, along with another neoantigen vaccine known as GEN-010.